Document is current

Article History

Received: 17 April 2024

Accepted: 2 July 2024

First Online: 18 July 2024

Declarations

:

: All data was pseudonymized. The Ethics Committee of the Medical Faculty at Heidelberg University Hospital raised no objections to the execution of the study (internal number S-377/2023). The study adhered to the most recent version of the Declaration of Helsinki.

: not applicable.

: PX has received speaker fees from Janssen, MSD and OMT outside the submitted work. PU: nothing to declare. HML has received consulting fees, speaking fees and/or honoraria and unallocated funds for scientific talks and consultations from Abbvie, Astra-Zeneca, Actelion, Alexion, Amgen, Bayer Vital, Baxter, Biogen, Boehringer Ingelheim, BMS, Celgene, Fresenius, Genzyme, GSK, Gilead/Galapagos, Hexal, Janssen-Cilag, Lilly, Medac, MSD, Mundipharm, Mylan, Novartis, octapharm, Pfizer, Roche/Chugai, Sandoz, Sanofi, Shire, SOBI, Thermo Fisher, UCB outside the submitted work. NBl: received research grants from SOBI and Novartis, and speaking honoraria from SOBI, Novartis, Roche, MSD, Abbott, Pfizer, Boehringer, Actelion and UCB. CAE received speaking fees from MSD outside the submitted work. SH received honoraria for lectures, consultancy, or both from Actelion, AOP, Bayer/MSD, GSK, Novartis, OMT, Pfizer, and United Therapeutics out-side the submitted work. BE received travel fees, consulting fees, speaking fees, and/or honoraria from Actelion, MSD, Bayer and OMT, outside the submitted work. JCG received consultant and speaker fees as well as research and travel grants from Janssen Pharmaceutical Companies of Johnson & Johnson; consultant fees from MSD and speaker fees from Inari. CPD received consultant fees and grants from GSK and Inventiva; consultant and speaker fees from Boehringer Ingelheim; consultant fees from Bayer, Corbus, CSL Behring, Roche and Sanofi; received speaker fees from Janssen Pharmaceutical Companies of Johnson & Johnson; and grants from ARXX Therapeutics and Servier. EG served as speaker and/or consultant honoraria for Bayer Healthcare, Ferrer, GEBRO, GlaxoSmithKline, Janssen Biotech, Merck Sharp & Dohme (MSD), and OMT outside the submitted work. EG received research funding for clinical studies from Acceleron, Actelion Pharmaceuticals, Bayer Health Care, MSD, Bellerophon, Gossamer Bio, Janssen, Novartis, OMT, Pfizer, REATE und United Therapeutics outside the submitted work. NBe: nothing to declare.